211 related articles for article (PubMed ID: 21473814)
1. Coverage with evidence development: the Ontario experience.
Levin L; Goeree R; Levine M; Krahn M; Easty T; Brown A; Henry D
Int J Technol Assess Health Care; 2011 Apr; 27(2):159-68. PubMed ID: 21473814
[TBL] [Abstract][Full Text] [Related]
2. Coverage with evidence development: merit for motherhood?
Koch P
Int J Technol Assess Health Care; 2011 Oct; 27(4):322; author reply 322-3. PubMed ID: 21936971
[No Abstract] [Full Text] [Related]
3. Health technology assessment in Australia: a role for clinical registries?
Scott AM
Aust Health Rev; 2017 Mar; 41(1):19-25. PubMed ID: 27028134
[TBL] [Abstract][Full Text] [Related]
4. Coverage with evidence development for pharmaceuticals: a policy in evolution?
Lexchin J
Int J Health Serv; 2011; 41(2):337-54. PubMed ID: 21563627
[TBL] [Abstract][Full Text] [Related]
5. Managed Entry Agreements: Policy Analysis From the European Perspective.
Dabbous M; Chachoua L; Caban A; Toumi M
Value Health; 2020 Apr; 23(4):425-433. PubMed ID: 32327159
[TBL] [Abstract][Full Text] [Related]
6. Building bridges between academic research and policy formulation: the PRUFE framework - an integral part of Ontario's evidence-based HTPA process.
Goeree R; Levin L
Pharmacoeconomics; 2006; 24(11):1143-56. PubMed ID: 17067198
[TBL] [Abstract][Full Text] [Related]
7. Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in Ireland.
Schmitz S; McCullagh L; Adams R; Barry M; Walsh C
Pharmacoeconomics; 2016 Sep; 34(9):925-37. PubMed ID: 27034245
[TBL] [Abstract][Full Text] [Related]
8. Budget impact analysis.
Leelahavarong P
J Med Assoc Thai; 2014 May; 97 Suppl 5():S65-71. PubMed ID: 24964701
[TBL] [Abstract][Full Text] [Related]
9. The clinical effectiveness and cost-effectiveness of technologies used to visualise the seizure focus in people with refractory epilepsy being considered for surgery: a systematic review and decision-analytical model.
Burch J; Hinde S; Palmer S; Beyer F; Minton J; Marson A; Wieshmann U; Woolacott N; Soares M
Health Technol Assess; 2012; 16(34):1-157, iii-iv. PubMed ID: 22985954
[TBL] [Abstract][Full Text] [Related]
10. Coverage with evidence development: an examination of conceptual and policy issues.
Hutton J; Trueman P; Henshall C
Int J Technol Assess Health Care; 2007; 23(4):425-32. PubMed ID: 17937829
[TBL] [Abstract][Full Text] [Related]
11. Representing uncertainty: the role of cost-effectiveness acceptability curves.
Fenwick E; Claxton K; Sculpher M
Health Econ; 2001 Dec; 10(8):779-87. PubMed ID: 11747057
[TBL] [Abstract][Full Text] [Related]
12. Early assessment of medical technologies to inform product development and market access: a review of methods and applications.
Ijzerman MJ; Steuten LM
Appl Health Econ Health Policy; 2011 Sep; 9(5):331-47. PubMed ID: 21875163
[TBL] [Abstract][Full Text] [Related]
13. Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries.
Kovács S; Kaló Z; Daubner-Bendes R; Kolasa K; Hren R; Tesar T; Reckers-Droog V; Brouwer W; Federici C; Drummond M; Zemplényi AT
Health Econ; 2022 Sep; 31 Suppl 1(Suppl 1):195-206. PubMed ID: 35322478
[TBL] [Abstract][Full Text] [Related]
14. Transparency vs. closed-door policy: do process characteristics have an impact on the outcomes of coverage decisions? A statistical analysis.
Fischer KE; Rogowski WH; Leidl R; Stollenwerk B
Health Policy; 2013 Oct; 112(3):187-96. PubMed ID: 23664301
[TBL] [Abstract][Full Text] [Related]
15. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.
Nicod E
Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758
[TBL] [Abstract][Full Text] [Related]
16. Evidence, appropriateness, and technology assessment in cardiology: a case study of computed tomography.
Redberg RF
Health Aff (Millwood); 2007; 26(1):86-95. PubMed ID: 17211017
[TBL] [Abstract][Full Text] [Related]
17. Establishing a comprehensive continuum from an evidentiary base to policy development for health technologies: the Ontario experience.
Levin L; Goeree R; Sikich N; Jorgensen B; Brouwers MC; Easty T; Zahn C
Int J Technol Assess Health Care; 2007; 23(3):299-309. PubMed ID: 17579931
[TBL] [Abstract][Full Text] [Related]
18. Decision tools in health care: focus on the problem, not the solution.
Liu J; Wyatt JC; Altman DG
BMC Med Inform Decis Mak; 2006 Jan; 6():4. PubMed ID: 16426446
[TBL] [Abstract][Full Text] [Related]
19. Evidence-based decision-making 3: Health technology assessment.
O'Reilly D; Campbell K; Vanstone M; Bowen JM; Schwartz L; Assasi N; Goeree R
Methods Mol Biol; 2015; 1281():417-41. PubMed ID: 25694325
[TBL] [Abstract][Full Text] [Related]
20. Uncertainty and Coverage With Evidence Development: Does Practice Meet Theory?
Pouwels XGLV; Grutters JPC; Bindels J; Ramaekers BLT; Joore MA
Value Health; 2019 Jul; 22(7):799-807. PubMed ID: 31277827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
